Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Decreases By 36.1%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 167,500 shares, a drop of 36.1% from the January 31st total of 262,100 shares. Currently, 6.1% of the company’s shares are sold short. Based on an average daily volume of 437,800 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP purchased a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 6.17% of the company’s stock.

Theriva Biologics Trading Down 2.3 %

NYSEAMERICAN TOVX traded down $0.03 during trading hours on Tuesday, hitting $1.30. 33,000 shares of the company’s stock were exchanged, compared to its average volume of 179,963. The firm has a 50-day moving average of $1.46. Theriva Biologics has a 1-year low of $1.14 and a 1-year high of $17.11. The stock has a market cap of $3.61 million, a price-to-earnings ratio of -0.04 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Separately, Maxim Group decreased their target price on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.